Scarica l'app Stockscreener
11.10
2.03%
-0.23
Dopo l'orario di chiusura:
11.10
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty - GuruFocus
Guggenheim Downgrades Benitec Biopharma(BNTC.US) to Hold Rating - Moomoo
The Technical Signals Behind (BNTC) That Institutions Follow - Stock Traders Daily
BNTC Stock Price, Quote & Chart - ChartMill
Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical SupportChannel Breakout - newsline.com
Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term OutlookGamma Flip Level - The Legal Advocate
Benitec Biopharma Announces Board Changes and New Director - The Globe and Mail
Benitec BiopharmaCFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 - marketscreener.com
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role - Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones - Stock Traders Daily
Benitec Biopharma (BNTC) Edges Higher Amid Steady TradingGolden Cross - The Legal Advocate
H.C. Wainwright Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - Sahm
Benitec Biopharma Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Company Overview - minichart.com.sg
Benitec Biopharma Reports Q3 2026 Results: Strong BB-301 Clinical Progress for OPMD, $184.8M in Cash, Upcoming FDA Milestones - Minichart
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Benitec Biopharma (BNTC) Fairly Valued After Q3 FY2026 Earnin - GuruFocus
Benitec Biopharma 3Q Loss/Shr 24c >BNTC - Moomoo
Benitec Biopharma Inc. Q3 2026: Revenue $0 Net loss $(11.9M), EPS $(0.24) — 10-Q Summary - TradingView
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
Benitec Biopharma (NASDAQ: BNTC) raises $100M to fund OPMD gene therapy BB-301 - Stock Titan
Benitec Biopharma Q3 net loss narrows as expenses fall - TradingView
BB-301 data, strong cash position shape Benitec (NASDAQ: BNTC) Q3 2026 - Stock Titan
BRIEF-Benitec Biopharma Q3 Operating Income USD -13.6 Million - TradingView
Evercore ISI initiates Benitec BioPharma stock coverage at outperform By Investing.com - Investing.com Australia
BNTC Initiates Coverage On Benitec Biopharma -- Rating Set to Ou - GuruFocus
Evercore ISI initiates Benitec BioPharma stock coverage at outperform - Investing.com UK
The scenario planning at Benitec (BNTC) | Q1 2026: Earnings Fall ShortSecondary Offering - Newser
The one metric that defines Benitec (BNTC) success (On the Radar) 2026-05-08Revenue Weighted - The Legal Advocate
Trading the Move, Not the Narrative: (BNTC) Edition - Stock Traders Daily
Benitec presents OPMD gene therapy data at May conference - Investing.com UK
Benitec presents OPMD gene therapy data at May conference By Investing.com - Investing.com India
Rare swallowing disease study posts 24-month follow-up at gene therapy meeting - Stock Titan
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - ChartMill
Biotech founder behind a $14.6B sale joins Seaport board - Stock Titan
Biotech founder behind $14.6B sale joins Seaport board - Stock Titan
(BNTC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Benitec (BNTC) Stock: Why Analysts Watch It (Breakout Watch) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):